Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk c19hcq.org Naseem et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,214 patients in Pakistan Lower mortality with HCQ (not stat. sig., p=0.34) Naseem et al., medRxiv, doi:10.1101/2020.12.13.20247254 Favors HCQ Favors control
Predicting mortality in SARS-COV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep Neural Network
Naseem et al., medRxiv, doi:10.1101/2020.12.13.20247254 (Preprint)
Naseem et al., Predicting mortality in SARS-COV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep.., medRxiv, doi:10.1101/2020.12.13.20247254 (Preprint)
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,214 hospitalized patients in Pakistan, 77 HCQ patients, showing 33% lower mortality with HCQ, multivariate Cox HR 0.67, p = 0.34.
risk of death, 33.3% lower, RR 0.67, p = 0.34, treatment 77, control 1,137, multivariate Cox.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Naseem et al., 14 Dec 2020, retrospective, Pakistan, preprint, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20247254; this version posted August 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Predicting mortality in SARS-COV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep Neural Network. Maleeha Naseem1, Hajra Arshad2, Syeda Amrah Hashmi2, Furqan Irfan3, Fahad Shabbir Ahmed4, 5, 6 1 Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan 74900. 2 Medical College, Aga Khan University, Karachi, Pakistan 74900. 3 College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824. 4 Clinicaro Machine Learning Group, New Haven, CT, 06510. 5 Department of Pathology, Wayne State University, Detroit, MI 48201. 6 Corresponding author Email Address: Fahad Shabbir Ahmed, fahadshabbirahmed@gmail.com Corresponding author: Fahad Shabbir Ahmed, Lead Scientist, Clinicaro Machine Learning group; Department of Pathology, Wayne State University / Detroit Medical Center. Harper Professional Building, 4160 John R St, Detroit, MI 48201. Phone: 631-644-3981; Email; fahadshabbirahmed@gmail.com. Conflict of Interest: None. Disclosures: None Abstract words count: 389 Manuscript word count: 2870 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20247254; this version posted August 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. ABSTRACT Background The second wave of COVID-19 pandemic is anticipated to be worse than the initial one and will strain the healthcare systems even more during the winter months. Our aim was to develop a machine learning-based model to predict mortality using the deep learning Neo-V framework. We hypothesized this novel machine learning approach could be applied to COVID-19 patients to predict mortality successfully with high accuracy. Methods The current Deep-Neo-V model is built on our previously statistically rigorous machine learning framework [Fahad-Liaqat-Ahmad Intensive Machine (FLAIM) framework] that evaluated statistically significant risk factors, generated new combined variables and then supply these risk factors to deep neural network to predict mortality in RT-PCR positive COVID-19 patients in the inpatient setting. We analyzed adult patients (≥18 years) admitted to the Aga Khan University Hospital, Pakistan with a working diagnosis of COVID-19 infection (n=1228). We excluded patients that were negative on COVID-19 on RT-PCR, had incomplete or missing health records. The first phase selection of risk factor was done using Cox-regression univariate and multivariate analyses. In the second phase, we generated new variables and tested those statistically significant for mortality and in the third and final phase we applied deep neural networks and other traditional machine learning models like Decision Tree Model, k-nearest neighbor models and others. Results A total of 1228 cases were diagnosed as COVID-19 infection, we excluded 14 patients after the exclusion criteria and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit